Defeat Duchenne Canada is pleased to share the latest Duchenne community letter from Solid Biosciences.

The letter outlines recent functional data from the ongoing IGNITE DMD Phase I/II clinical trials and plans for the dosing of additional patients by the end of the year. We will continue to monitor the progress of this trial and work with Solid Biosciences on including Canada in future trials.

Click the button below to read the full letter.